Special Issue "TCR Gene Therapy: Challenges, Opportunities and Future Directions"
A special issue of Cells (ISSN 2073-4409).
Deadline for manuscript submissions: closed (30 April 2020).
Interests: immunology—cancer-immunology, onco-immunology, gene therapy, and immunotherapy; T-cells—CD8 T-cells, CD4 T-cells, and Tregs; vector—lentivirus and retrovirus; antigen: neo-antigen and tumor-antigen; effector function—cytotoxicity, cytokine production, T-cell receptor, affinity, and avidity
Interests: cancer immunology; immuno-surveillance; cancer biology; inherited kidney cancer syndromes; early kidney cancer; von-Hippel Lindau syndrome; hereditary leiomyomatosis renal cell carcinoma; metabolic kidney cancer; clinical trials
In the past years, adoptive immunotherapy with gene-engineered T-cells has provided new treatment options for cancer patients. The most successful strategies have involved the engineering of T cells expressing chimeric antigen receptors (CARs) directed against differentiation antigens expressed in hematological malignancies. To date, clinical trials with TCR gene engineered T cells have not yet shown the impressive benefits seen with CAR constructs targeting CD19-positive blood cancers. In this Special Issue, we will discuss the opportunity to use the TCR technology to target cancer antigens, including mutated proteins, that cannot be reached by CAR technology. We will explore how TCR modifications and T-cell editing can improve the functional profile of engineered T cells, and review our current understanding of the TCR signaling mechanisms that enable T cell activation at exceedingly low concentrations of peptide antigens. This Issue provides detailed insight into the TCR biology and how it may enable the development of highly specific immunotherapies for the treatment of cancer.
Prof. Hans Stauss
Assoc. Prof. Maxine Tran
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Cancer immunotherapy
- TCR gene therapy
- Gene editing
- Adoptive cell therapy